Virus-like Particles for TEM Regulation and Antitumor Therapy
Source abstract
Abstract
Tumor development and metastasis are intimately associated with the tumor microenvironment (TME), and it is difficult for vector-restricted drugs to act on the TME for long-term cancer immunotherapy. Virus-like particles (VLPs) are nanocage structures self-assembled from nucleic acid free viral proteins. Most VLPs range from 20–200 nm in diameter and can naturally drain into lymph nodes to induce robust humoral immunity. As natural nucleic acid nanocarriers, their surfaces can also be genetically or chemically modified to achieve functions such as TME targeting. This review focuses on the design ideas of VLP as nanocarriers and the progress of their research in regulating TME.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bacteriophages and microbial interactions · RNA Interference and Gene Delivery · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Green Process and Engineering, State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China
School of Chemical Engineering, University of Chinese Academy of Sciences, Beijing 100049, China
School of Pharmacy, Heilongjiang University of Traditional Chinese Medicine, Harbin 150040, China
Funding
National Natural Science Foundation of China · Beijing Natural Science Foundation
References (92)
Show source-provided references
1. Hallmarks of Cancer: New Dimensions10.1158/2159-8290.CD-21-1059 ↗
2. Refining the Role for Adult Stem Cells as Cancer Cells of Origin10.1016/j.tcb.2014.08.008 ↗
3. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries10.3322/caac.21660 ↗
4. Cancer Statistics, 202210.3322/caac.21708 ↗
5. Cancer Incidence and Mortality in China, 201610.1016/j.jncc.2022.02.002 ↗
6. Self-Assembled Peptide and Protein Nanostructures for Anti-Cancer Therapy: Targeted Delivery, Stimuli-Responsive Devices and Immunotherapy10.1016/j.nantod.2021.101119 ↗
7. Effect of Bariatric Surgery on Cancer Risk: Results from an Emulated Target Trial Using Population-Based Data10.1093/bjs/znac003 ↗
8. Immunogenic Chemotherapy: Dose and Schedule Dependence and Combination with Immunotherapy10.1016/j.canlet.2018.01.050 ↗
9. Local Triple-Combination Therapy Results in Tumour Regression and Prevents Recurrence in a Colon Cancer Model10.1038/nmat4707 ↗
10. Early Tumor Detection Afforded by in Vivo Imaging of Near-Infrared II Fluorescence10.1016/j.biomaterials.2017.04.046 ↗
11. Benchmarking to the Gold Standard: Hyaluronan-Oxime Hydrogels Recapitulate Xenograft Models with In Vitro Breast Cancer Spheroid Culture10.1002/adma.201901166 ↗
12. Local MicroRNA Delivery Targets Palladin and Prevents Metastatic Breast Cancer10.1038/ncomms12868 ↗
13. Oxaliplatin-Loaded Chemically Cross-Linked Hydrogels for Prevention of Postoperative Abdominal Adhesion and Colorectal Cancer Therapy10.1016/j.ijpharm.2019.04.065 ↗
14. Plasmonic Photothermal Heating of Intraperitoneal Tumors through the Use of an Implanted Near-Infrared Source10.1021/nn4033757 ↗
15. Progress in Natural Compounds/SiRNA Co-Delivery Employing Nanovehicles for Cancer Therapy10.1021/acscombsci.0c00099 ↗
16. Recent Progress on Semiconducting Polymer Nanoparticles for Molecular Imaging and Cancer Phototherapy10.1016/j.biomaterials.2017.11.025 ↗
17. Versatile Polydopamine Platforms: Synthesis and Promising Applications for Surface Modification and Advanced Nanomedicine10.1021/acsnano.9b04436 ↗
18. Engineering Precision Nanoparticles for Drug Delivery10.1038/s41573-020-0090-8 ↗
19. Characterizing the Ecological and Evolutionary Dynamics of Cancer10.1038/s41588-020-0668-4 ↗
20. The Application of Nanoparticles in Cancer Immunotherapy: Targeting Tumor Microenvironment
21. Targeting Tumor-Associated Macrophages in Cancer10.1016/j.it.2019.02.003 ↗
22. Tumor-Associated Macrophages in Cancer: Recent Advancements in Cancer Nanoimmunotherapies10.1186/s13046-022-02272-x ↗
23. TCR-Vγδ Usage Distinguishes Protumor from Antitumor Intestinal Γδ T Cell Subsets10.1126/science.abj8695 ↗
24. IL-17-Producing Cells in Tumor Immunity: Friends or Foes?10.4110/in.2020.20.e6 ↗
25. Advantages of Targeting the Tumor Immune Microenvironment over Blocking Immune Checkpoint in Cancer Immunotherapy
26. The Role of the Tumor Microbe Microenvironment in the Tumor Immune Microenvironment: Bystander, Activator, or Inhibitor?10.1186/s13046-021-02128-w ↗
27. Caldeira, J.C., Perrine, M., Pericle, F., and Cavallo, F. (2020). Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines. Viruses, 12.10.3390/v12050488 ↗
28. He, J., Yu, L., Lin, X., Liu, X., Zhang, Y., Yang, F., and Deng, W. (2022). Virus-like Particles as Nanocarriers for Intracellular Delivery of Biomolecules and Compounds. Viruses, 14.10.3390/v14091905 ↗
29. The Application of Virus-like Particles as Vaccines and Biological Vehicles10.1007/s00253-015-7000-8 ↗
30. Virus-Like Particle: Evolving Meanings in Different Disciplines10.1089/phage.2020.0026 ↗
31. Bioengineering of Virus-like Particles as Dynamic Nanocarriers for in Vivo Delivery and Targeting to Solid Tumours10.1016/j.addr.2021.114030 ↗
32. A Smart Viral Vector for Targeted Delivery of Hydrophobic Drugs10.1038/s41598-021-86198-y ↗
33. Kim, K.-H., Kwon, Y.-M., Lee, Y.-T., Kim, M.-C., Hwang, H., Ko, E.-J., Lee, Y., Choi, H.-J., and Kang, S.-M. (2018). Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus. Vaccines, 6.10.3390/vaccines6040066 ↗
34. Targeted Delivery of Nanovaccine to Dendritic Cells via DC-Binding Peptides Induces Potent Antiviral Immunity in Vivo10.2147/IJN.S357462 ↗
35. Bioengineered Protein-Based Nanocage for Drug Delivery10.1016/j.addr.2016.03.002 ↗
36. Major Findings and Recent Advances in Virus–like Particle (VLP)-Based Vaccines10.1016/j.smim.2017.08.014 ↗
37. Purification of Flavivirus VLPs by a Two-Step Chomatographic Process10.1016/j.vaccine.2019.05.066 ↗
38. Chaudhuri, A., Kumar, D.N., Shaik, R.A., Eid, B.G., Abdel-Naim, A.B., Md, S., Ahmad, A., and Agrawal, A.K. (2022). Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy. IJMS, 23.10.3390/ijms231710068 ↗
39. Recent Developments in Functionalized Polymer Nanoparticles for Efficient Drug Delivery System10.1016/j.nanoso.2019.100397 ↗
40. Inorganic Nanoparticles Applied as Functional Therapeutics10.1002/adfm.202008171 ↗
41. Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases10.3389/fmicb.2021.790121 ↗
42. Virus-Like Particles as an Instrument of Vaccine Production10.1134/S0026893319030154 ↗
43. Virus-like Particles: Preparation, Immunogenicity and Their Roles as Nanovaccines and Drug Nanocarriers10.1186/s12951-021-00806-7 ↗
44. In Vitro Preparation of Uniform and Nucleic Acid Free Hepatitis B Core Particles through an Optimized Disassembly-Purification-Reassembly Process10.1016/j.pep.2020.105747 ↗
45. Principles of Nanoparticle Design for Overcoming Biological Barriers to Drug Delivery10.1038/nbt.3330 ↗
46. The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors10.1021/acs.chemrev.0c00779 ↗
47. Delivering Adjuvants and Antigens in Separate Nanoparticles Eliminates the Need of Physical Linkage for Effective Vaccination10.1016/j.jconrel.2017.02.031 ↗
48. Nanoparticles Target Distinct Dendritic Cell Populations According to Their Size10.1002/eji.200737984 ↗
49. Trafficking of JC Virus-like Particles across the Blood–Brain Barrier10.1039/D0NA00879F ↗
50. Size, Shape, Charge and “Stealthy” Surface: Carrier Properties Affect the Drug Circulation Time in Vivo10.1016/j.ajps.2020.07.005 ↗
51. Internalization and Antigen Presentation by Mouse Dendritic Cells of Rotavirus VP6 Preparations Differing in Nanostructure10.1016/j.molimm.2020.04.001 ↗
52. The Impact of Size on Particle Drainage Dynamics and Antibody Response10.1016/j.jconrel.2021.01.012 ↗
53. Genetic Engineering Strategies for Construction of Multivalent Chimeric VLPs Vaccines10.1080/14760584.2020.1738227 ↗
54. The Hepatitis B Virus Core Variants That Expose Foreign C-Terminal Insertions on the Outer Surface of Virus-Like Particles10.1007/s12033-015-9895-9 ↗
55. Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity10.1128/JVI.01123-15 ↗
56. A Biomimetic VLP Influenza Vaccine with Interior NP/Exterior M2e Antigens Constructed through a Temperature Shift-Based Encapsulation Strategy10.1016/j.vaccine.2020.07.015 ↗
57. A Virus-like Particle of the Hepatitis B Virus PreS Antigen Elicits Robust Neutralizing Antibodies and T Cell Responses in Mice10.1016/j.antiviral.2017.11.007 ↗
58. Peyret, H., Gehin, A., Thuenemann, E.C., Blond, D., El Turabi, A., Beales, L., Clarke, D., Gilbert, R.J.C., Fry, E.E., and Stuart, D.I. (2015). Tandem Fusion of Hepatitis B Core Antigen Allows Assembly of Virus-Like Particles in Bacteria and Plants with Enhanced Capacity to Accommodate Foreign Proteins. PLoS ONE, 10.10.1371/journal.pone.0120751 ↗
59. Antigenic and Cryo-Electron Microscopy Structure Analysis of a Chimeric Sapovirus Capsid10.1128/JVI.02916-15 ↗
60. Choosing an Effective Protein Bioconjugation Strategy10.1038/nchembio.720 ↗
61. Surface Functionalization of Virus-Like Particles by Direct Conjugation Using Azide−Alkyne Click Chemistry10.1021/bc100367u ↗
62. Click Chemistry Applied to the Synthesis of Salmonella Typhimurium O-Antigen Glycoconjugate Vaccine on Solid Phase with Sugar Recycling10.1021/acs.bioconjchem.5b00521 ↗
63. A Modular Vaccine Development Platform Based on Sortase-Mediated Site-Specific Tagging of Antigens onto Virus-Like Particles10.1038/srep25741 ↗
64. Switch from Polymorphic to Homogenous Self-Assembly of Virus-Like Particles of Simian Virus 40 through Double-Cysteine Substitution10.1002/smll.202004484 ↗
65. Improving the Malaria Transmission-Blocking Activity of a Plasmodium Falciparum 48/45 Based Vaccine Antigen by SpyTag/SpyCatcher Mediated Virus-like Display10.1016/j.vaccine.2017.05.054 ↗
66. New Routes and Opportunities for Modular Construction of Particulate Vaccines: Stick, Click, and Glue10.3389/fimmu.2018.01432 ↗
67. Emerging Concepts in the Science of Vaccine Adjuvants10.1038/s41573-021-00163-y ↗
68. Virus-like Particles against Infectious Disease and Cancer: Guidance for the Nano-Architect10.1016/j.copbio.2021.09.012 ↗
69. Mohsen, M., Gomes, A., Vogel, M., and Bachmann, M. (2018). Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System. Vaccines, 6.10.3390/vaccines6030037 ↗
70. Jobsri, J., Allen, A., Rajagopal, D., Shipton, M., Kanyuka, K., Lomonossoff, G.P., Ottensmeier, C., Diebold, S.S., Stevenson, F.K., and Savelyeva, N. (2015). Plant Virus Particles Carrying Tumour Antigen Activate TLR7 and Induce High Levels of Protective Antibody. PLoS ONE, 10.10.1371/journal.pone.0118096 ↗
71. Recognition of Double-Stranded RNA and Activation of NF-ΚB by Toll-like Receptor 310.1038/35099560 ↗
72. Comparative Efficacy of Virus like Particle (VLP) Vaccine of Foot-and-Mouth-Disease Virus (FMDV) Type O Adjuvanted with Poly I:C or CpG in Guinea Pigs10.1016/j.biologicals.2015.09.004 ↗
73. The Effect of the Tumor Microenvironment and Tumor-Derived Metabolites on Dendritic Cell Function10.7150/jca.38785 ↗
74. Tumor Microenvironment-Related Dendritic Cell Deficiency: A Target to Enhance Tumor Immunotherapy10.1016/j.phrs.2020.104980 ↗
75. Glycan-Modified Virus-like Particles Evoke T Helper Type 1-like Immune Responses10.1021/acsnano.0c03023 ↗
76. Antigen Incorporated In Virus-like Particles Is Delivered to Specific Dendritic Cell Subsets That Induce An Effective Antitumor Immune Response In Vivo10.1097/CJI.0b013e3182787f5e ↗
77. Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines10.3389/fimmu.2017.00226 ↗
78. Therapeutic HPV DNA Vaccines10.1007/s12026-009-8141-6 ↗
79. Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody10.1021/acs.nanolett.5b05030 ↗
80. Macrophages as Tools and Targets in Cancer Therapy10.1038/s41573-022-00520-5 ↗
81. Inhibitory Functions of PD-L1 and PD-L2 in the Regulation of Anti-Tumor Immunity in Murine Tumor Microenvironment10.1007/s00262-018-2263-4 ↗
82. The Antitumor Efficacy of CpG Oligonucleotides Is Improved by Encapsulation in Plant Virus-Like Particles10.1002/adfm.201908743 ↗
83. In Situ Biomimetic Nanoformulation for Metastatic Cancer Immunotherapy10.1016/j.actbio.2021.07.055 ↗
84. Addition of TLR9 Agonist Immunotherapy to Radiation Improves Systemic Antitumor Activity10.1016/j.tranon.2020.100983 ↗
85. Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity10.3389/fimmu.2017.01454 ↗
86. Coexpression of CD49b and LAG-3 Identifies Human and Mouse T Regulatory Type 1 Cells10.1038/nm.3179 ↗
87. Regulatory T Cells in Cancer Immunotherapy10.1038/cr.2016.151 ↗
88. Boosting Antitumor Response with PSMA-Targeted Immunomodulatory VLPs, Harboring Costimulatory TNFSF Ligands and GM-CSF Cytokine10.1016/j.omto.2022.02.010 ↗
89. Bovine Papillomavirus Prostate Cancer Antigen Virus-like Particle Vaccines Are Efficacious in Advanced Cancers in the TRAMP Mouse Spontaneous Prostate Cancer Model10.1007/s00262-020-02493-z ↗
90. Nanoparticle-Based Co-Delivery of SiRNA and Paclitaxel for Dual-Targeting of Glioblastoma10.2217/nnm-2020-0066 ↗
91. Synthesis and Assembly of Hepatitis B Virus-Like Particles in a Pichia Pastoris Cell-Free System10.3389/fbioe.2020.00072 ↗
92. Doxorubicin-Loaded Physalis Mottle Virus Particles Function as a PH-Responsive Prodrug Enabling Cancer Therapy10.1002/biot.202000077 ↗